Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia
Christie M. Ballantyne, Szilárd Vasas, Masoud Azizad, et al.
New England Journal of Medicine (2024) Vol. 391, Iss. 10, pp. 899-912
Closed Access | Times Cited: 63

Showing 1-25 of 63 citing articles:

Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia
Robert S. Rosenson, Daniel Gaudet, Robert A. Hegele, et al.
New England Journal of Medicine (2024) Vol. 391, Iss. 10, pp. 913-925
Closed Access | Times Cited: 67
Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk
Gerald F. Watts, Robert S. Rosenson, Robert A. Hegele, et al.
New England Journal of Medicine (2024)
Closed Access | Times Cited: 38
Epidemiology and longitudinal course of chylomicronemia: Insights from NHANES and a large health care system
Seyedmohammad Saadatagah, Mohammadreza Naderian, Miriam Larouche, et al.
Journal of clinical lipidology (2025)
Open Access | Times Cited: 2
Impact of remnant cholesterol on short-term and long-term prognosis in patients with prediabetes or diabetes undergoing coronary artery bypass grafting: a large-scale cohort study
Zhongchen Li, Chunyu Yu, Heng Zhang, et al.
Cardiovascular Diabetology (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Current and Emerging Treatment Options for Hypertriglyceridemia: State-of-the-Art Review
Jakub Michał Zimodro, Manfredi Rizzo, Ioanna Gouni‐Berthold
Pharmaceuticals (2025) Vol. 18, Iss. 2, pp. 147-147
Open Access | Times Cited: 1
Novel RNA-Based Therapies in the Management of Dyslipidemias
Constantine E. Kosmas, Maria D. Bousvarou, Donatos Tsamoulis, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 3, pp. 1026-1026
Open Access | Times Cited: 1
Familial chylomicronemia syndrome and treatments to target hepatic APOC3 mRNA
Eliot A. Brinton, Robert H. Eckel, Daniel Gaudet, et al.
Atherosclerosis (2025), pp. 119114-119114
Closed Access | Times Cited: 1
Association of remnant cholesterol with unhealthy lifestyle and risk of coronary heart disease: a population-based cohort study
Mia Østergaard Johansen, Signe Vedel‐Krogh, Sune F. Nielsen, et al.
The Lancet Regional Health - Europe (2025), pp. 101223-101223
Open Access | Times Cited: 1
Discordance Analyses Comparing LDL Cholesterol, Non-HDL Cholesterol, and Apolipoprotein B for Cardiovascular Risk Estimation
Camilla Ditlev Lindhardt Johannesen, Martin Bødtker Mortensen, Børge G. Nordestgaard, et al.
Atherosclerosis (2025) Vol. 403, pp. 119139-119139
Closed Access | Times Cited: 1
The Year in Cardiovascular Medicine 2024: the top 10 papers in dyslipidaemias
Lâle Tokgözoğlu, Carl E. Orringer, Alberico L. Catapano
European Heart Journal (2025)
Closed Access | Times Cited: 1
Etiology and emerging treatments for familial chylomicronemia syndrome
Catherine M. Spagnuolo, Robert A. Hegele
Expert Review of Endocrinology & Metabolism (2024) Vol. 19, Iss. 4, pp. 299-306
Open Access | Times Cited: 6
Interaction Between Primary Hyperlipidemias and Type 2 Diabetes: Therapeutic Implications
Rafael Zubirán, Ivette Cruz‐Bautista, Carlos A. Aguilar‐Salinas
Diabetes Therapy (2024) Vol. 15, Iss. 9, pp. 1979-2000
Open Access | Times Cited: 5
Hypertriglyceridemia Therapy: Past, Present and Future Perspectives
Ileana Canfora, Sabata Pierno
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 17, pp. 9727-9727
Open Access | Times Cited: 5
Olezarsen, a liver-directed APOC3 ASO therapy for hypertriglyceridemia
Amanda J. Hooper, Damon A. Bell, John R. Burnett
Expert Opinion on Pharmacotherapy (2024)
Closed Access | Times Cited: 4
Exploring emerging pharmacotherapies for type 2 diabetes patients with hypertriglyceridemia
Brian Tomlinson, Paul Chan
Expert Opinion on Pharmacotherapy (2025), pp. 1-11
Closed Access
Approach to Lipid Management in the Patient with Diabetes
Stephanie Kim, Savitha Subramanian
The Journal of Clinical Endocrinology & Metabolism (2025)
Open Access
Diagnosis, Evaluation, and Management of Severe Hypertriglyceridemia
Amrita Krishnamurthy, Edwin A. Homan, Samuel M. Kim
Current Cardiovascular Risk Reports (2025) Vol. 19, Iss. 1
Closed Access
Efficacy of Apolipoprotein-C3 Inhibitors in the Treatment of Hypertriglyceridemia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
Milene Vitória Sampaio Sobral, Ivo Queiroz, João Pedro Pereira dos Santos, et al.
American Journal of Therapeutics (2025)
Closed Access
Molecular Therapeutics in Development to Treat Hyperlipoproteinemia
Maud Ahmad, Robert A. Hegele
Molecular Diagnosis & Therapy (2025)
Open Access
Leveraging drug-target Mendelian randomization for tailored lipoprotein-lipid lowering
Éloi Gagnon, Benoît J. Arsenault
Current Opinion in Lipidology (2025)
Closed Access
siRNA-based Delivery Systems: Technologies, Carriers, Applications, and Approved Products
Parisa Ghasemiyeh, Soliman Mohammadi‐Samani
European Journal of Pharmacology (2025), pp. 177441-177441
Closed Access
Reaching for the stars: a wider perspective for designing future cardiovascular outcome trials of triglyceride-lowering therapies
Gerald F. Watts, Dick C. Chan
European Heart Journal (2025)
Closed Access
Evaluating the Cardiometabolic Efficacy and Safety of Lipoprotein Lipase Pathway Targets in Combination With Approved Lipid-Lowering Targets: A Drug Target Mendelian Randomization Study
Éloi Gagnon, Dipender Gill, Dominique Chabot, et al.
Circulation Genomic and Precision Medicine (2025)
Closed Access
Design and Rationale of the CORE –TIMI 72a and CORE2 –TIMI 72b Trials of Olezarsen in Patients with Severe Hypertriglyceridemia
Nicholas Marston, Brian A. Bergmark, Veronica J. Alexander, et al.
American Heart Journal (2025)
Closed Access
Apolipoprotein C-III inhibitors for the treatment of hypertriglyceridemia: A meta-analysis of randomized controlled trials
Mariana de Moura de Souza, Beatriz Ximenes Mendes, Maria Luiza Rodrigues Defante, et al.
Metabolism (2025), pp. 156187-156187
Closed Access
Page 1 - Next Page

Scroll to top